Aurinia Pharmaceuticals (NASDAQ:AUPH) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) released its quarterly earnings data on Thursday. The biotechnology company reported $0.09 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.04, Zacks reports. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. Aurinia Pharmaceuticals updated its FY 2025 guidance to EPS.

Aurinia Pharmaceuticals Trading Down 4.3 %

Shares of Aurinia Pharmaceuticals stock traded down $0.35 on Thursday, hitting $7.61. 3,586,261 shares of the company’s stock traded hands, compared to its average volume of 1,327,625. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -50.72 and a beta of 1.22. The company has a fifty day moving average of $8.22 and a two-hundred day moving average of $7.77. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.